Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754421 | 0.92 | KMT2A (0.33) | ANPEPERAP2MEN1KMT2A | |
| SCHEMBL25754418 | 0.84 | ANPEP (0.33) | ANPEPERAP2MEN1KMT2A | |
| SCHEMBL25754425 | 0.83 | PSMB1 (0.33) | LMNAKDM4E | |
| SCHEMBL25754420 | 0.82 | ANPEP (0.31) | ANPEPERAP2MEN1KMT2A | |
| SCHEMBL25754439 | 0.82 | KMT2A (0.33) | ANPEPERAP2MEN1KMT2A | |
| SCHEMBL25754524 | 0.79 | KMT2A (0.38) | ANPEPERAP2MEN1KMT2AATM | |
| SCHEMBL25754506 | 0.77 | KMT2A (0.38) | ANPEPERAP2MEN1KMT2AATM | |
| SCHEMBL25754411 | 0.75 | HRH3 (0.33) | LMNAKDM4E | |
| SCHEMBL25754467 | 0.75 | ABCB1 (0.36) | ANPEPERAP2MEN1KMT2APOLB | |
| SCHEMBL28301902 | 0.70 | MEN1 (0.46) | ANPEPERAP2MEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | ANPEP 273/4885ERAP2 447/4885MEN1 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.